Literature DB >> 8786247

Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression.

R A Sweet1, B G Pollock, M Kirshner, B Wright, L P Altieri, C L DeVane.   

Abstract

A study of a dopaminergic antidepressant that may have an advantageous profile for use in elderly patients, bupropion, was conducted to determine the pharmacokinetics of bupropion in the elderly. Pharmacokinetics of single- and multiple-dose bupropion were examined in six elderly patients (five women and one man) diagnosed with depression. Mean (+/- SD) CL app of bupropion was 1.6 +/- 0.4 L/hr/kg, approximately 80% of the corresponding value reported for younger patients. Mean bupropion t1/2 was 34.2 +/- 8.7 hours, and average apparent Vd (Vd app) was 79.3 +/- 29.4 L/kg. Apparent half-lives (t1/2 app) of the metabolites hydroxybupropion, erythrobupropion, and threohydrobupropion were 34.2 +/- 4.6 hours, 61.4 +/- 21.6 hours, and 38.8 +/- 7.6 hours, respectively. After multiple dosing, the mean t1/2 for bupropion and its metabolites did not change significantly, although in some patients the t1/2 app of the metabolites was substantially prolonged. There was also evidence of inordinate accumulation of metabolites. The elderly are at risk for accumulation of bupropion and its metabolites. Specification of therapeutic drug monitoring parameters for bupropion treatment of the elderly is needed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8786247     DOI: 10.1002/j.1552-4604.1995.tb04132.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  19 in total

Review 1.  Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation.

Authors:  Andrew J Johnston; John Ascher; Robert Leadbetter; Virginia D Schmith; Dipak K Patel; Michael Durcan; Beth Bentley
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information.

Authors:  Richard D Boyce; Steven M Handler; Jordan F Karp; Joseph T Hanlon
Journal:  Am J Geriatr Pharmacother       Date:  2012-01-27

Review 3.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

4.  Non-tricyclic and Non-selective Serotonin Reuptake Inhibitor Antidepressants and Recurrent Falls in Frail Older Women.

Authors:  Jennifer G Naples; Mary P Kotlarczyk; Subashan Perera; Susan L Greenspan; Joseph T Hanlon
Journal:  Am J Geriatr Psychiatry       Date:  2016-08-17       Impact factor: 4.105

Review 5.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 6.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

7.  Studies in formulation and pharmacotechnical evaluation of controlled release transdermal delivery system of bupropion.

Authors:  Deepak Gondaliya; Kilambi Pundarikakshudu
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

8.  Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach.

Authors:  Paul K Kiptoo; Kalpana S Paudel; Dana C Hammell; Raghotham Reddy Pinninti; Jianhong Chen; Peter A Crooks; Audra L Stinchcomb
Journal:  J Pharm Sci       Date:  2009-02       Impact factor: 3.534

Review 9.  Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents.

Authors:  A J Flint
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

10.  Extended treatment of older cigarette smokers.

Authors:  Sharon M Hall; Gary L Humfleet; Ricardo F Muñoz; Victor I Reus; Julie A Robbins; Judith J Prochaska
Journal:  Addiction       Date:  2009-04-09       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.